NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Thursday. The brokerage set a “sell” rating on the ...

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

Marianna De León told Newsweek that she would not be able to live a full life had she not had them again after serious health ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the journal Blood.

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Equities research analysts at Wedbush boosted their FY2024 EPS estimates for Apellis Pharmaceuticals in a research report ...